

Date: July 31, 2025

To
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

Scrip Code: **532041**

Dear Sir/Madam,


Sub: Outcome of Board Meeting held on Thursday, July 31, 2025 as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015[“SEBI(LODR), 2015”]

Pursuant to Regulation 30 and other applicable Regulations of SEBI (LODR), 2015, the Board of Directors of the Company in its meeting held today i.e., on July 31, 2025:

1. Approved the Un-Audited Standalone Financial Results of the company for the First Quarter ended on June 30, 2025 along with the Limited Review Report.
2. Took note of resignation of Mr. Devanshu Ravinder Dange (A76053), Associate Member of the Institute of Company Secretaries of India (ICSI), from the position of Company Secretary, Compliance Officer and Key Managerial Personnel of the Company with effect from closing business hours of July 31, 2025 due to personal reasons.
3. Appointed Mr. Shailendra Vyas, Associate Member of ICSI, having Membership No: A77193, as Company Secretary, Key Managerial Personnel and Compliance Officer of the Company with effect from August 01, 2025 in terms of Section 203 of the Companies Act, 2013 read with Rule 8 of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and Regulation 6 of the SEBI (LODR), 2015.
4. Considered and approved the notice of 33rd Annual General Meeting along with the Directors report and Corporate Governance report for the FY ended on March 31, 2025.
5. Fixed the date and venue of the 33rd Annual General meeting – September 30, 2025 at 10:00 AM at the registered office of the Company.

HINDUSTAN BIOSCIENCES LTD.

#31, Sagar Society, Road No. 2,
Banjara Hills, Hyderabad - 500 034, INDIA.



+91 40 23555161 / 23555181
pharma.hindustanbio@gmail.com
www.hindustan.bio
CIN : L26942TG1991PLC013564

6. Considered and adopted Secretarial Audit Report for the Financial year 2024-25 issued by Mr. VBSS Prasad, Practicing Company Secretary (PCS).
7. Appointed Mr. VBSS Prasad, PCS as scrutinizer for conducting E-voting in the ensuing 33rd Annual General Meeting.

Further, pursuant to Regulation 30 of SEBI (LODR), 2015 and the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 (including any statutory modification(s) or amendment(s) or re-enactment(s) thereof, for the time being in force):

- the details pertaining to the resignation of Mr. Devanshu Ravinder Dange are mentioned in **Annexure - 1** and the resignation letter is attached as **Annexure - 2**; and
- the details pertaining to the appointment of Mr. Shailendra Vyas are mentioned in **Annexure-3**.


The meeting commenced at 02:00 P.M. and concluded at **04:15 PM**

This is for your information and records.

Thanking You,
For Hindustan Bio Sciences Limited



J V R Mohan Raju
Managing Director
DIN: 00060800



Change in Key Managerial Personnel:


Resignation of Mr. Devanshu Ravinder Dange (A76053) as the Company Secretary, Compliance Officer and Key Managerial Personnel of the Company.

Name in Full	Mr. Devanshu Ravinder Dange
Designation	Company Secretary, Key Managerial Personnel & Compliance Officer
Reason for Change viz. appointment, resignation, removal, death or otherwise	Resignation
Date of appointment / Cessation (as applicable) & term of appointment/re-appointment	From the closing business hours of Thursday, July 31, 2025
Brief Profile (in case of appointment)	Not Applicable
Disclosures of relationships between Directors (In case of appointment of Director)	Not Applicable

For Hindustan Bio Sciences Limited



V R Mohan Raju
Managing Director
DIN: 00060800



Annexure - 2

Date: July 31, 2025

To
The Board of Directors,
Hindustan Bio Sciences Limited,
Plot No.31, Sagar Society,
Road No.2 Banjara Hills,
Hyderabad, Telangana – 500034.

Sub: Resignation from the post of Company Secretary, Compliance Officer and Key Managerial Personnel of Hindustan Bio Sciences Limited.

Dear Sir/Madam,

I hereby tender my resignation as Company Secretary, Compliance Officer and Key Managerial Personnel of Hindustan Bio Sciences Limited with effect from the closing business hours of July 31, 2025 due to my personal reasons.

Further, I confirm that there is no other material reason for my resignation apart from the reason mentioned above.

I hereby convey my sincere thanks to the Board of Directors and senior management for their support and cooperation extended during my tenure as Company Secretary and Compliance Officer of the Company. My best wishes are with the company and its management in all its future endeavours.

I request the management to kindly acknowledge the receipt of my resignation and file the necessary documents and forms required both with the Registrar of Companies and the Stock Exchange.

Thanking you,
Best Regards,




CS Devanshu Ravinder Dange
M. No. A76053


Change in Key Managerial Personnel:

Appointment of Mr. Shailendra Vyas (A77193) as the Company Secretary, Key Managerial Personnel & Compliance officer of the Company.

Name in Full	Mr. Shailendra Vyas
Designation	Company Secretary, Key Managerial Personnel & Compliance Officer
Reason for Change viz. appointment, resignation, removal, death or otherwise	Appointed on account of resignation of the previous Company Secretary
Date of appointment / Cessation (as applicable) & term of appointment	w.e.f., August 01, 2025
Brief Profile (in case of appointment)	Mr. Shailendra Vyas (A77193) is an Associate Member of the Institute of Company Secretaries of India (ICSI). He holds a Bachelors Degree in Commerce (Computer Applications) from Telangana University and a Bachelors Degree in Law (LL.B.) from Osmania University.
Disclosures of relationships between Directors (In case of appointment of Director)	Not Applicable

For Hindustan Bio Sciences Limited


 J V R Mohan Raju
 Managing Director
 DIN: 00060800



HINDUSTAN BIOSCIENCES LTD.

#31, Sagar Society, Road No. 2,
 Banjara Hills, Hyderabad - 500 034, INDIA.

+91 40 23555161 / 23555181
 pharma.hindustanbio@gmail.com
 www.hindustan.bio
 CIN : L26942TG1991PLC013564

HINDUSTAN BIO SCIENCES LIMITED
CIN: L26942TG1991PLC03564

Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034
Phone No. 23555161, Fax 40205171

STATEMENT OF UN- AUDITED RESULTS FOR THE QUARTER ENDED ON 30TH JUNE,2025

Sl. No.	Particulars	Quarter ended			Rs. In Lakhs
		30-06-2025 (unaudited)	31.03.2025 (Audited)	30-06-2024 (unaudited)	31.03.2025 (Audited)
1	Income from Operations				
	(a) Revenue from operations	32.19	37.53	41.11	81.33
	(b) Other Income	1.31	1.26	1.43	0
	Total Revenue (1)	33.50	38.79	42.54	81.33
2	Expenses				
	(a) cost of material consumed	-	-	-	-
	(b) Purchases of Stock -in-trade	21.19	23.68	25.71	49.39
	(c) Changes in Inventories of finished goods, Stock - in-Trade and Work-in-Progress	-	-	-	-
	(d) Employee Benefit Expenses	4.40	3.31	3.01	12.58
	(e) Finance Costs	0.05	0.05	0.03	0.14
	(f) Selling Expenses	0.15	0.00	0.09	0.00
	(g) Depreciation and amortisation Expenses	0.00	-0.07	0.03	0.02
	(h) Other Expenses	6.32	1.02	5.49	9.38
	Total Expenses(2)	32.11	28.00	34.36	71.51
3	Profit/(Loss) before Exceptional& Extraordinary items and tax (1 -2)	1.40	10.79	8.18	9.82
4	Exceptional items	-	-	-	-
5	Profit/(Loss) before tax(3 -4)	1.40	10.79	8.18	9.82
6	Tax Expenses				
	(a) Current Tax	-	-	-	-
	(b) Previous Taxes	-	-	-	(0.26)
	(b) Deferred Tax	0	0	0	-
7	Profit /(Loss) for the period from continuing operations(5-6)	1.40	10.79	8.18	10.08
8	Profit /(Loss) from discontinued operations	-	-	-	-
9	Tax Expense of discontinued operations	-	-	-	-
10	Profit /Loss from Discontinued operations after tax(8-9)	-	-	-	-
11	Profit/(Loss) for the period(7+10)	1.40	10.79	8.18	10.08
12	Other Comprehensive Income				
	A (1) Items that will not be reclassified to profit or loss	-	-	-	-
	(2) Income tax relating to items that will not be re- classified to profit or loss	-	-	-	-
	B (1) Items that will be reclassified to profit or loss	-	-	-	-
	(2) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
13	Total Comprehensive Income for the period (11+12) (comprising Profit (Loss) and other comprehensive income for the period	1.40	10.79	8.18	10.08
14	Paid up Equity Capital(Face value of Rs. 2/- each)	205.02	205.02	205.02	205.02
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				(114.52)
16	Earnings per equity share for continuing operations				
	(A) Basic	0.01	0.11	0.08	0.10
	(B) Diluted	0.01	0.11	0.08	0.10
17	Earnings per equity share for discontinuing operations				
	(A) Basic	-	-	-	-
	(B) Diluted	-	-	-	-
18	Earnings per equity share(for discontinuing & continuing operations				
	(A) Basic	0.01	0.11	0.08	0.10
	(B) Diluted	0.01	0.11	0.08	0.10

Notes:

1. The above standalone results for the quarter ended 30th June 2025 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 31st July 2025. The statutory auditors have expressed an unmodified audit opinion.

2. This statement is as per regulation 33 of the SEBI (LODR) Regulations, 2015.


3. The Company operates in one reportable business segment i.e., Trading of Pharmaceuticals. Hence segmental reporting as per Ind AS 108 is not applicable.

4. The results for the Quarter ended 30th June, 2025 are also available on the website of BSE Limited and on the Company's website.

5. Figures for the previous periods have been rearranged/reclassified wherever necessary to conform to the current period presentation.

Place: Hyderabad
Date: 31-07-2025

J V R Mohan Raju
Managing Director
(DIN: 00060800)





VASG & ASSOCIATES
Chartered Accountants

503/A, 5th Floor, Kubera Towers,
Narayanaguda, Hyderabad - 500 029.
Ph : 040-66849660
E-mail : info@vasg-ca.com
vasgassociates@gmail.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
STANDALONE FINANCIAL RESULTS**

TO THE BOARD OF DIRECTORS OF
M/S HINDUSTAN BIO SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited financial results of HINDUSTAN BIO SCIENCES LIMITED (the "Company"), for the quarter and period ended June 30, 2025, being prepared by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended.

The preparation of this statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ("IND AS 34"), prescribed under section 133 of the companies act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India is the responsibility of the company's management and has been approved by the Board of Directors of the company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s VASG & Associates
Chartered Accountants

FRN:006070S


A. Viswanatha Rao
(partner)

M.no:029597

UDIN: 25029597BMIXND4708

Date:31.07.2025

Place:Hyderabad